A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas.
Farace F, Massard C, Vimond N, Drusch F, Jacques N, Billiot F, Laplanche A, Chauchereau A, Lacroix L, Planchard D, Le Moulec S, André F, Fizazi K, Soria JC, Vielh P. · 2011
Read A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. by Farace F, Massard C, Vimond N, Drusch F, Jacques N, Billiot F, Laplanche A, Chauchereau A, Lacroix L, Planchard D, Le Moulec S, André F, Fizazi K, Soria JC, Vielh P. (2011) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3171010.txt.
Introduction
Françoise Farace and colleagues compared two machines that count tumour cells circulating in blood in a 2011 paper in the British Journal of Cancer. Such counts forecast patient outlook and treatment success, but no universal detection method exists. One system fishes cells out by a surface marker; the other filters by cell size. Sixty patients with spreading breast, prostate, or lung cancer gave samples to both.
The two systems agreed in just over half of breast and prostate cases, and in only a fifth of lung cases. Size-based counts often found cells the marker method missed. The authors warn that marker-only capture can overlook tumour cells that have shed the marker while turning more aggressive, a bias worst in lung cancer. Counts from the two methods should never be treated as interchangeable.
Catalog record
| CREATOR | Farace F, Massard C, Vimond N, Drusch F, Jacques N, Billiot F, Laplanche A, Chauchereau A, Lacroix L, Planchard D, Le Moulec S, André F, Fizazi K, Soria JC, Vielh P. |
|---|---|
| YEAR | 2011 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 30 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas By F Farace, C Massard, N Vimond, F Drusch, N Jacques, F Billiot, A Laplanche, A Chauchereau, L Lacroix, D Planchard, S Le Moulec, F André Published in: British Journal of Cancer DOI: 10.1038/bjc.2011.294 ABSTRACT Background: Circulating tumour cells (CTCs) can provide information on patient prognosis and treatment efficacy. However, there is no universal method to detect CTC currently available. Here, we compared the performance of two CTC detection systems based on the expression of the EpCAM antigen (CellSearch assay) or on cell size (ISET assay). Methods: Circulating tumour cells were enumerated in 60 patients with metastatic carcinomas of breast, prostate and lung origins using CellSearch according to the manufacturer's protocol and ISET by studying cytomorphology and immunolabelling with anti-cytokeratin or lineage-specific antibodies. Results: Concordant results were obtained in 55% (11 out of 20) of the patients with breast cancer, in 60% (12 out of 20) of the patients with prostate cancer and in only 20% (4 out of 20) of lung cancer patients. Conclusion: Our results highlight important discrepancies between the numbers of CTC enumerated by both techniques. These differences depend mostly on the tumour type. These results suggest that technologies limiting CTC capture to EpCAM-positive cells, may present important limitations, especially in patients with metastatic lung carcinoma. Metastatic dissemination of malignant solid tumours is the main cause of death by cancer in the developed countries. The metastatic cascade is defined as a series of biological events that cancer cells from the primary neoplasia must complete to develop a new malignancy at a distant site, including the crucial step consisting in the release and survival of tumour cells in the peripheral blood (Sahai, 2007). These circulating tumour cells (CTCs) consist in a heterogeneous population of very rare cells native of either the primary tumour or its own metastasis (Mocellin et al, 2006; Sahai, 2007; Alix-Panabières et al, 2008). Key molecular events involved in metastatic progression are likely to have considerable effects on the number and on the phenotype of CTC. In this regard, experimental data suggest that biological processes such as the epithelial-to-mesenchymal transition (EMT), associated with the acquisition of cancer stem cell properties and resistance to conventional therapy, might have a role in the generation of more aggressive sub-populations of CTC (Polyak and Weinberg, 2009; Mego et al, 2010). Although the existence of CTC has been known for over a hundred of years, only the recent advent of novel cytometric (i.e., whole cell based) technologies have enabled significant progress in detecting and quantifying these cells. Using the CellSearch platform (Veridex, Warren, NJ, USA), several groups have shown an association between the counts of CTC identified by the assay and patients’ clinical outcome (Cristofanilli et al, 2004; Cohen et al, 2008; De Bono et al, 2008). Circulating tumour cell levels were indeed prospectively demonstrated to be an independent prognostic factor in patients with advanced breast, prostate and colorectal cancers treated by conventional and/or hormonal therapy (Cristofanilli et al, 2004; Cohen et al, 2008; De Bono et al, 2008). Moreover, longitudinal monitoring also indicated a potential role for enumerating CTC as an endpoint biomarker making it possible to predict, at an early stage, whether a patient benefits or not from anticancer treatment (Hayes et al, 2006). In addition to prognostic and predictive utility, CTC also represent a unique non-invasive source of tumour material susceptible to provide real-time information on the patient's current disease status. New possibilities with important clinical implications therefore concern the molecular characterisation of CTC since it could be incorporated in future clinical designs to monitor the efficacy of or resistance to targeted therapy. Numerous technical efforts have been made to reliably detect and quantify CTC, but the development of a universal assay has proven quite difficult. Circulating tumour cells are indeed very rare events, occurring at rates as low as one cell per 106 or 107 leukocytes and most methods rely on the combination of two steps, that is, enrichment followed by detection to increase the sensitivity of the assay (Mostert et al, 2009). Another major technical challenge concerns tumour heterogeneity. Gene-expression profiling has highlighted the remarkable heterogeneity of malignant cells not only within a given histological subtype but also among tumour cells of any given patient. In addition to genetic instability inherent to most neoplastic cell types, emerging data suggest that cell-biological changes during metastatic progression, such as the transition between epithelial-to-mesenchymal states, can also generate distinct multiple cellular sub-populations contributing to intratumoural heterogeneity (Polyak and Weinberg, 2009; Thiery et al, 2009; Mego et al, 2010). Owing to this heterogeneity, the assay used for CTC detection could strongly impact on the biomarker value of CTC, and data regarding CTC should therefore be interpreted in the context of this method. A rather limited number of studies comparing the performance of different assays and providing data to support the choice of a given method have been published (Lambrechts et al, 1999; Smith et al, 2000; Ring et al, 2005; Van der Auwera et al, 2010). This study was designed to directly compare the performance of two cytometric (i.e., CellSearch and ISET) systems based on different CTC properties, namely the expression of an epithelial antigen membrane vs cell size. The standardised and semi-automated CellSearch platform is the only assay currently approved by the Food and Drug Administration. Circulating tumour cell enrichment by CellSearch is based on the expression of the epithelial-lineage marker EpCAM (epithelial cell adhesion molecule). EpCAM-positive cells are enriched by immunomagnetic separation using EpCAM-specific antibodies conjugated to magnetic particles and then stained with fluorescent anti-cytokeratin and 4′,6-diamino-2-phenylindole (DAPI), while hematopoietic cells are stained with anti-CD45 antibodies. Cytokeratin and DAPI-positive, and CD45-negative CTC are finally counted by using a semi-automated fluorescent microscope (Cristofanilli et al, 2004; Hayes et al, 2006; Cohen et al, 2008; De Bono et al, 2008). ISET (isolation by size of epithelial tumour cells) makes it possible to collect tumour cells based on their larger size as cells are enriched by blood filtration through filtering membranes with calibrated pores 8 μm in diameter (Vona et al, 2000, 2004; Paterlini-Brechot and Benali, 2007). Enriched cells are stained on the filter for cytomorphological examination or further characterised by immunocytochemistry. As the performance of CTC detection assays may also be influenced by intrinsic characteristics of different tumour types, this study comprises 60 patients with metastatic carcinomas of breast, prostate and lung origins. PATIENTS AND METHODS Blood sample collection This study was approved by our institutional review board and local ethics committee. Informed and written consent was obtained from all patients. Peripheral blood samples were collected from 60 patients with histologically or cytologically confirmed metastatic breast (n=20), prostate (n=20) or non-small cell lung cancer (n=20). Clinico-pathologic information was recorded for all patients. For each patient, 10 ml of blood was collected in EDTA tubes (Terumo, Leuven, Belgium) for CTC enumeration by ISET and 7.5 ml was collected in CellSave collection tubes (Immunicon Inc., Huntingdon Valley, PA, USA) for the CellSearch test. Enumeration of CTC by CellSearch Circulating tumour cell enumeration using the CellSearch system (Veridex LLC, Raritan, NJ, USA) was carried out according to the manufacturer's protocol and training. Blood samples were processed